Improving the global management of the neurogenic bladder patient: part II.Future treatment strategies

References

• Kelleher CJ, Cardozo LD, Khullar V, et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988–93
   PubMedGoogle Scholar
• Bennett N, O’Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004;171:749–51
   PubMed Web of Science ®Google Scholar
• Denys P, Corcos J, Everaert K, et al. Improving the global management of the neurogenic bladder patient: part I. The complexity of patients. Curr Med Res Opin 2006;22:359–65
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004;64:1643–56
   PubMed Web of Science ®Google Scholar
• Anderson K-E, Appell R, Cardozo L, et al. Chapter 14: pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khuory S, Wein A, editors. Incontinence, vol. 2, management. Plymouth (UK): Health Publication Ltd; 2005. p. 809–54
   Google Scholar
• Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 2004;42:267–72
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ, Castro D, Madersbacher H, et al. Chapter 17: neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khuory S, Wein A, editors. Incontinence, vol 2, management. Plymouth (UK): Health Publication Ltd; 2005. p. 1059–162
   Google Scholar
• Andersson KE, Chapple C. Oxybutinin and the overactive bladder. World J Urol 2001;19:319–23
   PubMed Web of Science ®Google Scholar
• Pesce F, Rubilotta E, D’Amico A, et al. Long-term anticholinergic therapy: duration and causes of discontinuation. Presented at ICS, Florence, 2003
   Google Scholar
• Stohrer M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia – a double-blind, placebo-controlled clinical trial. Spinal Cord 1999;37:196–200
   PubMed Web of Science ®Google Scholar
• Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433–46
   PubMed Web of Science ®Google Scholar
• Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the permissible anticholinergic dosage [abstract 527]. Presented at the International Continence Society 35th Annual Meeting, Montreal, 2005
   Google Scholar
• Mazo EB, Krivoborodov GG, Shkol’nikov ME, et al. Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity. Urologia 2005;July–August:56–9
   Google Scholar
• Van Kerrebroeck PE, Amarenco G, Thuroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyper-reflexia. Neurourol Urodyn 1998;17:499–512
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al.; OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687–95
   Google Scholar
• Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358–63
   PubMed Web of Science ®Google Scholar
• Wyllie MG. Uroselectivity: end of the road? Br J Urol Int 2003;92:141–2
   Google Scholar
• Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005;23: 248–52
   Google Scholar
• Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006;147(Suppl 2): S80–S87
   Google Scholar
• Yucel S, Akkaya E, Guntekin E, et al. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Urology 2005;65:369–73
   PubMed Web of Science ®Google Scholar
• Buyse G, Verpoorten C, Vereecken R, et al. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 1998;160:1084–7
   PubMed Web of Science ®Google Scholar
• Saito M, Watanabe T, Tabuchi F, et al. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 2004;11:592–6
   PubMed Web of Science ®Google Scholar
• Glickman S, Tsokkos N, Shah PJ. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia 1995;33:36–9
   Google Scholar
• Deaney C, Glickman S, Gluck T, et al. Intravesical atropine suppression of detrusor hyperreflexia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;65:957–8
   PubMed Web of Science ®Google Scholar
• Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor Dysfunct 1998;9:100–2
   PubMedGoogle Scholar
• Radziszewski P, Borkowski A. Therapeutic effects of intrarectal administration of oxybutynin. Wiad Lek 2002;55:691–8
   PubMedGoogle Scholar
• De Wachter S, Wyndaele JJ. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 2003;169: 1892–5
   PubMed Web of Science ®Google Scholar
• Fowler C. Intravesical treatment of overactive bladder. Urology 2000;55(Suppl 5A):60–4
   Google Scholar
• De Ridder D, Chandiramani V, Dasgupta P, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997;158:2087–92
   PubMed Web of Science ®Google Scholar
• de Seze M, Wiart L, Joseph PA, et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998;17:513–23
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002;167:1710–4
   PubMed Web of Science ®Google Scholar
• Lazzeri M, Beneforti P, Spinelli M, et al. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 2000;164:676–9
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172:240–3
   PubMed Web of Science ®Google Scholar
• Stohrer M, Schurch B, Kramer G, et al. Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 1999;18:401–2
   Google Scholar
• Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692–7
   PubMed Web of Science ®Google Scholar
• Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510–5
   PubMed Web of Science ®Google Scholar
• Schurch B, de Seze M, Denys P, et al. Botulinum toxin is a safe and effective treatment for neurogenic urinary incontinence: results from a single-treatment, randomized, placebo-controlled 6-month study. J Urol 2005;174:196–200
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Michael T, Sturzebecher B, et al. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003;44:139–43
   Google Scholar
• Rackley R, Abdelmalak J. Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 2004;5:381–8
   PubMedGoogle Scholar
• Schurch B, Reitz A. Botox in urology: a new treatment modality without limitations? EAU Update Series 2004;2:170–8
   Google Scholar
• Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004;171:2128–37
   PubMed Web of Science ®Google Scholar
• Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984–9
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005;48:984–90
   Google Scholar
• Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004;46:784–91
   PubMed Web of Science ®Google Scholar
• Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patient with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47: 653–9
   Google Scholar
• Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865–70
   Google Scholar
• Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 2005;19:880–2
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644–50
   Google Scholar
• Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39: 1815–20
   PubMed Web of Science ®Google Scholar
• Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006;13[Suppl 1]:2–10
   Google Scholar
• Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005;20:937–44
   PubMed Web of Science ®Google Scholar
• Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005;21:433–8
   PubMed Web of Science ®Google Scholar
• Simonetta Moreau M, Cauhepe C, Magues JP, et al. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149:1041–5
   Web of Science ®Google Scholar
• Del Popolo G, Li Marzi V, Panariello G, et al. English botulinum toxin-A in the treatment of neurogenic detrusor overactivity [abstract 96]. Presented at the International Continence Society 33rd Annual Meeting, Florence, 2003
   Google Scholar
• Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71:24–6
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599–600
   PubMed Web of Science ®Google Scholar
• Patki P, et al. Botulinum-A toxin (Dysport) in the treatment of drug resistant neurogenic detrusor overactivity following traumatic spinal cord injury. Br J Urol Int 2006 [in press]
   Google Scholar
• Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 2006 13(Suppl 1):11–5
   PubMed Web of Science ®Google Scholar
• Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174:1873–7
   PubMed Web of Science ®Google Scholar
• Lazzeri M, Calo G, Spinelli M, et al. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/ orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol 2001;166:2237–40
   PubMed Web of Science ®Google Scholar
• Lazzeri M, Calo G, Spinelli M, et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology 2003;61:946–50
   PubMed Web of Science ®Google Scholar
• Jan CR, Lu YC, Jiann BP, et al. Novel effect of CP55,940, a CB1/CB2 cannabinoid receptor agonist, on intracellular free Ca2+ levels in bladder cancer cells. Chin J Physiol 2002;45:33–9
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol 2003;2:291–8
   PubMed Web of Science ®Google Scholar
• Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425–33
   PubMed Web of Science ®Google Scholar